Additionally, we have provided the first evidence that pharmacological inhibition of Gal-3 with DAVANAT® attenuated autoimmune cholangitis, suppressed serum levels of anti-PDC-E2 IgA, AST and ALT, expression of NLRP3 inflammasome, IL-1β production and influx of T1, T2, and T17 cells in the liver, and reduced liver fibrosis. The gene discussed is NLRP3; the disease is Hepatic fibrosis.